Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future

Related Articles

Dell's AI Transformation: How a $51 Billion Backlog Redefines its Future, Despite Margin Headwinds

2 months ago

Is Infosys's Acquisition Strategy Fueling Future Growth

5 months ago

What Does Apple's Executive Exodus Signal for Its Future

5 months ago

ClearBridge Redefines "Dividend Strategy": Why AI Hardware is the New Defensive Play

2 months ago

Category

You may also like

News•2 days ago

Health Care's Next Act: Tailwinds Emerging Across R&D Cycle

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation. Companies like JNJ and AZN, with diversified portfolios...

Share

Stock News•3 weeks ago

Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience and Redx Pharma agreed to combine, creating Nasdaq-listed Fibrx Therapeutics, a fibrosis-focused company led by Redx management. Concurrent financings of ~$125 million will fund operat...

SKYE

Share

Stock News•2 months ago

Here's Why Zymeworks Inc. Paid $929M For Theravance Biopharma

Zymeworks acquired Theravance Biopharma for $929M, gaining Yupelri's ~$60M annual cash flows with patent protection to 2039, diversifying beyond oncology and reducing equity reliance.

ZYME

Share